Loading...

Oncopeptides

DB:OND
Snowflake Description

Flawless balance sheet with moderate growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
OND
DB
SEK6B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Oncopeptides AB (publ), a clinical development pharmaceutical company, develops anti-cancer drugs. The last earnings update was 58 days ago. More info.


Add to Portfolio Compare Print
OND Share Price and Events
7 Day Returns
-1.7%
DB:OND
-2.4%
DE Biotechs
1.8%
DE Market
1 Year Returns
16%
DB:OND
-10.2%
DE Biotechs
-6%
DE Market
OND Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Oncopeptides (OND) -1.7% -0.4% -2.7% 16% - -
DE Biotechs -2.4% 3.2% -7.7% -10.2% 51.2% 10.1%
DE Market 1.8% 4.6% 7.4% -6% 10.1% 15.3%
1 Year Return vs Industry and Market
  • OND outperformed the Biotechs industry which returned -10.2% over the past year.
  • OND outperformed the Market in Germany which returned -6% over the past year.
Price Volatility
OND
Industry
5yr Volatility vs Market

Value

 Is Oncopeptides undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Oncopeptides. This is due to cash flow or dividend data being unavailable. The share price is €12.09.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Oncopeptides's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Oncopeptides's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:OND PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in SEK SEK-9.77
OM:ONCO Share Price ** OM (2019-04-18) in SEK SEK128.9
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.59x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Oncopeptides.

DB:OND PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= OM:ONCO Share Price ÷ EPS (both in SEK)

= 128.9 ÷ -9.77

-13.19x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Oncopeptides is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Oncopeptides is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Oncopeptides's expected growth come at a high price?
Raw Data
DB:OND PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -13.19x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts
49.7%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Oncopeptides, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Oncopeptides's assets?
Raw Data
DB:OND PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in SEK SEK6.47
OM:ONCO Share Price * OM (2019-04-18) in SEK SEK128.9
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.84x
DB:OND PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= OM:ONCO Share Price ÷ Book Value per Share (both in SEK)

= 128.9 ÷ 6.47

19.93x

* Primary Listing of Oncopeptides.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Oncopeptides is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Oncopeptides's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Oncopeptides has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Oncopeptides expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
49.7%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Oncopeptides expected to grow at an attractive rate?
  • Oncopeptides's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Oncopeptides's earnings growth is expected to exceed the Germany market average.
  • Unable to compare Oncopeptides's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:OND Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:OND Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts 49.7%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:OND Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in SEK Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:OND Future Estimates Data
Date (Data in SEK Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2022-12-31 1,517 780 683 1
2021-12-31 623 18 11 3
2020-12-31 356 -483 -483 2
2019-12-31 0 -560 -541 2
DB:OND Past Financials Data
Date (Data in SEK Millions) Revenue Cash Flow Net Income *
2018-12-31 -334 -419
2018-09-30 -271 -377
2018-06-30 -262 -325
2018-03-31 -244 -249
2017-12-31 -271 -250
2017-09-30 -270 -243
2017-06-30 -211 -216
2017-03-31 -159 -172
2016-12-31 -104 -125

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Oncopeptides's earnings are expected to grow significantly at over 20% yearly.
  • Unable to determine if Oncopeptides is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:OND Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from Oncopeptides Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:OND Future Estimates Data
Date (Data in SEK Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2022-12-31 15.20 15.20 15.20 1.00
2021-12-31 0.54 7.50 -9.80 3.00
2020-12-31 -9.71 -6.95 -12.47 2.00
2019-12-31 -10.90 -9.46 -12.33 2.00
DB:OND Past Financials Data
Date (Data in SEK Millions) EPS *
2018-12-31 -9.77
2018-09-30 -8.90
2018-06-30 -7.86
2018-03-31 -6.16
2017-12-31 -6.44
2017-09-30 -6.57
2017-06-30 -6.29
2017-03-31 -5.79
2016-12-31 -4.88

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Oncopeptides will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Oncopeptides's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Oncopeptides has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Oncopeptides performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Oncopeptides's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Oncopeptides does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Oncopeptides's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Oncopeptides's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Oncopeptides's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Oncopeptides Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:OND Past Revenue, Cash Flow and Net Income Data
Date (Data in SEK Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 -419.45 106.42 322.05
2018-09-30 -376.72 99.86 284.67
2018-06-30 -325.31 79.58 255.55
2018-03-31 -249.50 47.08 206.85
2017-12-31 -249.55 49.85 197.77
2017-09-30 -242.94 51.79 180.21
2017-06-30 -216.03 52.79 152.31
2017-03-31 -172.26 37.54 123.78
2016-12-31 -125.42 24.76 89.73
2015-12-31 -61.97 9.50 43.85
2014-12-31 -38.37 33.10

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Oncopeptides has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Oncopeptides has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Oncopeptides improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Oncopeptides's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Oncopeptides has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Oncopeptides's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Oncopeptides's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Oncopeptides is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Oncopeptides's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Oncopeptides's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Oncopeptides has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Oncopeptides Company Filings, last reported 3 months ago.

DB:OND Past Debt and Equity Data
Date (Data in SEK Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 315.83 0.00 375.62
2018-09-30 420.65 0.00 488.87
2018-06-30 510.24 0.00 568.21
2018-03-31 652.03 0.00 664.94
2017-12-31 418.01 0.00 404.05
2017-09-30 477.00 0.00 442.96
2017-06-30 533.40 0.00 535.07
2017-03-31 604.00 0.00 611.60
2016-12-31 26.34 0.00 40.25
2015-12-31 -2.60 0.00 2.29
2014-12-31 7.61 0.00 11.97
  • Oncopeptides has no debt.
  • Oncopeptides has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Oncopeptides has sufficient cash runway for 1.1 years based on current free cash flow.
  • Oncopeptides has sufficient cash runway for 1.1 years if free cash flow continues to grow at historical rates of 41.2% each year.
X
Financial health checks
We assess Oncopeptides's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Oncopeptides has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Oncopeptides's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Oncopeptides dividends. Estimated to be 0.13% next year.
If you bought €2,000 of Oncopeptides shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Oncopeptides's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Oncopeptides's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:OND Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:OND Future Dividends Estimate Data
Date (Data in SEK) Dividend per Share (annual) Avg. No. Analysts
2022-12-31
2021-12-31 0.50 2.00
2020-12-31 0.00 2.00
2019-12-31 0.00 2.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Oncopeptides has not reported any payouts.
  • Unable to verify if Oncopeptides's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Oncopeptides's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Oncopeptides has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Oncopeptides's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Oncopeptides's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Oncopeptides afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Oncopeptides has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Oncopeptides's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Jakob Lindberg
COMPENSATION SEK4,537,000
AGE 46
TENURE AS CEO 7.5 years
CEO Bio

Dr. Jakob Lindberg, Med. Lic has been the Chief Executive officer of Oncopeptides AB since October 2011. Dr. Lindberg is a Venture Partner at Investor Growth Capital Europe. He is the Owner of Cellectricon AB. He was a Vice President of Investor Growth Capital AB. Dr. Lindberg joined Investor Growth Capital in 2005. He focused on investments in life sciences and healthcare sector. Dr. Lindberg was a Co-Founder at Cellectricon AB and served as its Chief Executive Officer from 2000 to 2004. He has worked at McKinsey & Co. as an active member of healthcare practice. He served as a Director at Atlas Antibodies AB, Åmic AB and Heartscape Technologies, Inc. He serves as a Director of NeuroNova AB and Affibody Medical AB (publ). Dr. Lindberg serves as Director of Affibody Holding AB (also known as, Affibody AB). He served as an Independent Director of Alligator Bioscience AB (publ) since 2013 until May 2, 2017. He served as a Director of Cellectricon AB and SciBase AB. He served as a Director of Dipylon Medical AB. He served as Non-Executive Director of Newron Pharmaceuticals S.p.A. since December 17, 2012. He served as a Director of Sidec Technologies AB. He holds a Med. Lic in Molecular Immunology and a MSc in pre-clinical medicine from the Karolinska Institutet. Dr. Lindberg is a licensed Swedish physician with an M.D. from the Karolinska Institute and a B.A. in Finance and Administration from Stockholm University.

CEO Compensation
  • Jakob's compensation has increased whilst company is loss making.
  • Jakob's remuneration is lower than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Oncopeptides management team in years:

2.2
Average Tenure
53
Average Age
  • The tenure for the Oncopeptides management team is about average.
Management Team

Jakob Lindberg

TITLE
Chief Executive Officer
COMPENSATION
SEK5M
AGE
46
TENURE
7.5 yrs

Rolf Larsson

TITLE

Rolf Lewensohn

TITLE

Joachim Gullbo

TITLE

Kristina Luthman

TITLE

Hans Ehrsson

TITLE

Peter Nygren

TITLE
AGE
59

Anders Martin-Löf

TITLE
Chief Financial Officer
AGE
47
TENURE
0.4 yrs

Christians Jacques

TITLE
Executive VP of Clinical Strategy
TENURE
1.1 yrs

Rein Piir

TITLE
Head of Investor Relations
AGE
60
TENURE
3.3 yrs
Board of Directors Tenure

Average tenure and age of the Oncopeptides board of directors in years:

3.7
Average Tenure
60
Average Age
  • The tenure for the Oncopeptides board of directors is about average.
Board of Directors

Per Wold-Olsen

TITLE
Chairman
TENURE
0.9 yrs

Christians Jacques

TITLE
Executive VP of Clinical Strategy

Cecilia Wennborg

TITLE
Director
COMPENSATION
SEK303K
AGE
55
TENURE
2.2 yrs

Jonas Brambeck

TITLE
Director
AGE
60
TENURE
11.3 yrs

Jarl Jungnelius

TITLE
Director
COMPENSATION
SEK228K
AGE
67
TENURE
8 yrs

Per Anders Samuelsson

TITLE
Director
AGE
57
TENURE
7.3 yrs

Olof Tydén

TITLE
Director
COMPENSATION
SEK228K
AGE
71
TENURE
5.3 yrs

Brian Stuglik

TITLE
Director
TENURE
0.9 yrs

Jennifer Jackson

TITLE
Director
TENURE
0.3 yrs

Paul Richardson

TITLE
Member of Clinical Advisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
24. Sep 18 Sell Eva Nordström Individual 24. Sep 18 24. Sep 18 -6,000 €15.45 €-92,699
16. Aug 18 Buy Cecilia Wennborg Individual 16. Aug 18 16. Aug 18 4,000 €14.29 €57,132
05. Aug 18 Buy Eva Nordström Individual 02. Aug 18 02. Aug 18 151,200 €0.01 €1,614
02. Aug 18 Sell Fredrik Lehmann Individual 02. Aug 18 02. Aug 18 -11,100 €15.02 €-166,608
13. Jul 18 Sell Elisabeth Augustsson Individual 13. Jul 18 13. Jul 18 -1,000 €19.26 €-19,257
13. Jul 18 Sell Fredrik Lehmann Individual 13. Jul 18 13. Jul 18 -1,000 €19.24 €-19,238
X
Management checks
We assess Oncopeptides's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Oncopeptides has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Oncopeptides AB (publ), a clinical development pharmaceutical company, develops anti-cancer drugs. It develops Ygalo, a cytotoxic therapy that is in late-stage development use for the treatment of multiple myeloma. The company was founded in 2000 and is headquartered in Stockholm, Sweden.

Details
Name: Oncopeptides AB (publ)
OND
Exchange: DB
Founded: 2000
SEK602,191,347
48,841,921
Website: http://www.oncopeptides.se
Address: Oncopeptides AB (publ)
Vastra Tradgardsgatan 15,
Stockholm,
Stockholm County, 111 53,
Sweden
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
OM ONCO Ordinary Shares OMX Nordic Exchange Stockholm SE SEK 22. Feb 2017
DB OND Ordinary Shares Deutsche Boerse AG DE EUR 22. Feb 2017
LSE 0RN4 Ordinary Shares London Stock Exchange GB SEK 22. Feb 2017
Number of employees
Current staff
Staff numbers
27
Oncopeptides employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/21 21:57
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/03/28
Last earnings filing: 2019/02/22
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.